Ceftaroline fosamil: a new broad-spectrum cephalosporin (Q37863942)

24 August 2017

1 reference

title

Ceftaroline fosamil: a new broad-spectrum cephalosporin (English)

1 reference

24 August 2017

1 reference

ChEBI release 2020-05-28

Joseph B Laudano

1

1 reference

24 August 2017

language of work or name

English

0 references

publication date

1 April 2011

1 reference

Journal of Antimicrobial Chemotherapy

24 August 2017

published in

1 reference

24 August 2017

volume

66 Suppl 3

1 reference

24 August 2017

page(s)

iii11-8

1 reference

Trends in broad-spectrum antibiotic prescribing for children with acute otitis media in the United States, 1998-2004

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR095

Antibiotic prescribing over the last 16 years: fewer antibiotics but the spectrum is broadening.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR095

Ten years of antibiotic consumption in ambulatory care: trends in prescribing practice and antibiotic resistance in Austria

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR095

CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR095

CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR095

FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR095

FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR095

TAK-599, a novel N-Phosphono type prodrug of anti-MRSA cephalosporin T-91825: synthesis, physicochemical and pharmacological properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR095

Ceftaroline: a novel broad-spectrum cephalosporin with activity against meticillin-resistant Staphylococcus aureus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR095

Binding of ceftaroline to penicillin-binding proteins of Staphylococcus aureus and Streptococcus pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR095

Beta-lactams against methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR095

Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR095

Co-opting the cell wall in fighting methicillin-resistant Staphylococcus aureus: potent inhibition of PBP 2a by two anti-MRSA beta-lactam antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR095

Molecular basis and phenotype of methicillin resistance in Staphylococcus aureus and insights into new beta-lactams that meet the challenge.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR095

In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR095

Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR095

In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR095

Activity of the new cephalosporin ceftaroline against bacteraemia isolates from patients with community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR095

In vitro activity of ceftaroline against Streptococcus pneumoniae isolates exhibiting resistance to penicillin, amoxicillin, and cefotaxime.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR095

Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR095

In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR095

In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR095

In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR095

Ceftaroline: a new cephalosporin with activity against resistant gram-positive pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR095

Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR095

In vitro antimicrobial activity of T-91825, a novel anti-MRSA cephalosporin, and in vivo anti-MRSA activity of its prodrug, TAK-599.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR095

Postantibiotic effect of ceftaroline against gram-positive organisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR095

Effect of ceftaroline on normal human intestinal microflora.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR095

Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR095

Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR095

Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR095

Antibiotic stewardship programmes--what's missing?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR095

21 January 2018

Identifiers

DOI

10.1093/JAC/DKR095

1 reference

release_psc2ogamtffuri46jbpoloomsu

24 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/psc2ogamtffuri46jbpoloomsu

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference